San Diego’s Maravai LifeSciences has purchased MockV Solutions for undisclosed terms, it was announced March 17.

Maravai said the acquisition adds to its experience in bioprocess impurity testing, an important step in the manufacturing of therapies. It first entered the market by buying Cygnus Technologies.

“Viral contamination is an inherent risk during the manufacture of therapeutic products such as antibodies, vaccines, and plasma derivatives,” the company said in a statement. “Whether introduced initially from raw materials or later through specific manufacturing operations, unmitigated viral contamination has led to serious health implications and plant shutdowns.”

GTCR, a Chicago-based private equity firm, started Maravai. It specializes in buying life sciences firm that are ready to scale up.

MockV Solutions is headquartered in Baltimore.